Deutsch
A A A
Bereichsnavigation

Previous
RHÖN-KLINIKUM AG | 06/08/2016

Annual General Meeting of RHÖN-KLINIKUM AG on 8th June 2016 in Frankfurt/Main

Bad Neustadt/ Saale, 8th June 2016

Financial Figures 2015

  • 765,109 patients treated
  • Revenues amount to € 1.11 billion
  • EBITDA stands at € 154.2 million
  • Net consolidated profit is at € 87.4 million
  • Dividend proposal of € 0.80 per share

Results for 1st Quarter 2016

  • 205,578 patients treated
  • Revenues amount to € 291.5 million
  • EBITDA of € 67.9 million includes positive one-off effect of roughly € 36 million
  • Outlook for 2016: Revenues between € 1.17 billion and € 1.20 billion,
    EBITDA between € 155 million and € 165 million

 

“RHÖN-KLINIKUM AG has continued its strategic re-orientation in a targeted manner: concentrating on maximum cutting-edge medical care, raising treatment excellence, putting our campus concept into practice, network medicine and further developing eHealth – that is our corporate DNA,” CEO Dr. Martin Siebert explained at the Company’s Annual General Meeting in Frankfurt today. The corporate group wishes and will continue to be a principal driver of innovation in healthcare. The group-wide innovation and investment pool is therefore currently assisting a total of 60 research projects intending to promote discernible medical and nursing advances. Examples include a databank for brain tumours in order to be able to apply personalised therapy methods to a greater extent in the future. A further project includes an extensive risk and safety analysis which is to establish standards for all of the hospitals. “The power of innovation and the wealth of ideas in our Company are prodigious. All our activities are not just for our gain, however: they all have the same aim to raise the quality of treatment for our patients. Their wellbeing will also be at the centre of our activities in the future,” Siebert continued.

Just like the business development the number of patients was again influenced in the past financial year by the sales transaction with Fresenius/Helios which was concluded in 2014, even if to a significantly less extent. Exactly 765,109 patients were treated at the five sites of the Company in 2015. Revenues amounted to € 1.11 billion with earnings before interest, taxes, depreciation and amortisation (EBITDA) standing at € 154.2 million. Net consolidated profit was at € 87.4 million. For the current financial year the Company expects revenues of € 1.17 billion to € 1.20 billion and EBITDA (earnings before interest, taxes, depreciation and amortisation) of between € 155 million and € 165 million.

Proposal: Dividend of € 0.80 per Share

The Board of Management and Supervisory Board proposed to the AGM the distribution of a dividend in the amount of € 0.80 per share resulting in a dividend amount of € 53.6 million based on the current number of 66.96 million shares. RHÖN-KLINIKUM AG also intends the shareholders to be able to participate in the future success of the Company by means of dividend payout ratios which are above 60 % unless other value-adding growth options can be realised, such as acquiring hospitals.

Positive Developments at our Hospitals

Siebert pointed out that the Company is constantly investing in building structures, medical instruments and qualifications for the employees. All five hospitals had developed positively during the past financial year.

Building the new healthcare campus in Bad Neustadt is making good progress. A ground-breaking pilot project to link out-patient and in-patient treatment in a rural area will be realised here by 2018.

Another milestone in the past financial year was taking the particle therapy unit in Marburg into service. The first patients have now been treated at this unit which is unique in the world for treating certain types of cancer.

The cornerstone for the next stage of construction has been laid in Frankfurt/Oder in order to continue to modernise the hospital infrastructure and building structure. The facilities in Bad Berka and Giessen have also been further modernised, even if to a lesser extent, and they are now prepared for the challenges of the future.

Digitalisation and Innovation as a Central Component of the Corporate Strategy

Siebert explained that the healthcare system is entering a new age. Digitalisation, i.e. collecting, evaluating and interpreting patient data, will change medical care and the quality of treatment for ever. “With the help of digital data processing it is possible to give the patient significantly better treatment and structural and regional differences can be evened out, such as differences between cities on the one hand and rural areas on the other hand. Our campus concept, i.e. linking different medical services at one location, will both drive this technological development forwards and benefit from it at the same time.”

Siebert pointed out that a further thrust of digitalisation will take place in a regulated market suffering from restrictions, lack of investment and partial underfunding.  Digitalisation is therefore also an answer to many challenges because incorrect referrals can be avoided and therapy can be tailormade to individual patients due to information being managed better. This generates significant savings and therefore considerably improved efficiency for the entire healthcare system. “RHÖN-KLINIKUM AG tackles future topics in an offensive way. With various activities and initiatives we shall exploit the opportunities digitalisation has to offer our patients and therefore also contribute to the successful further development of our Company.”